 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | TmPSMA-02 / Gilead
Enrollment open, Metastases: TmPSMA-02 in mCRPC (clinicaltrials.gov) - Feb 6, 2024
P1, N=18, Recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting
- || TmPSMA-02 / Gilead
New P1 trial, Metastases: TmPSMA-02 in mCRPC (clinicaltrials.gov) - Sep 21, 2023
P1, N=18, Not yet recruiting, Sponsor: University of Pennsylvania
- | TmPSMA-02 / Gilead
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Aug 18, 2023
P1/2, N=1, Terminated, Sponsor: Tceleron Therapeutics, Inc.
N=114 --> 1 | Trial completion date: Jan 2032 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2028 --> May 2023; Study was stopped Sponsor discretion. No patients were dosed.
- || TmPSMA-02 / Gilead
Enrollment closed, Metastases: A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Dec 21, 2022
P1/2, N=114, Active, not recruiting, Sponsor: Tmunity Therapeutics
No patients were dosed. Recruiting --> Active, not recruiting
- ||| TmPSMA-02 / Gilead
Enrollment open, Metastases: A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Oct 19, 2022
P1/2, N=114, Recruiting, Sponsor: Tmunity Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- CART-PSMA- TGFβRDN cells / Tmunity Therap, TmPSMA-02 / Tmunity Therap
Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_672;
P1
Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275 ) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)...Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC...The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study.
- |||| TmPSMA-02 / Gilead
New P1/2 trial, Metastases: A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Aug 5, 2022
P1/2, N=114, Not yet recruiting, Sponsor: Tmunity Therapeutics